Advice on asthma diagnosis has been updated under newly published GP Quality and Outcomes Framework (QOF) guidance for 2025/26 so it no longer conflicts with separate UK joint guidelines issued last autumn by NICE.
Last November, the long-awaited UK asthma guide produced by NICE, the British Thoracic Society (BTS) and the Scottish Intercollegiate Guidelines Network (SIGN) revealed significant changes to recommendations on testing, which were different to QOF advice.
However, now the two have been reconciled – QOF guidance published last week has replaced indicator AST011 that refers to initial diagnosis with a new one, AST012. Points and targets for the indicator remain unchanged (see box below).
‘This indicator was updated… to reflect the recommendations made within the new combined asthma guideline produced by the BTS, NICE and the SIGN in November 2024,’ the guidance has said.
It added: ‘A combination of a suggestive clinical history and a supporting objective test is needed to diagnose asthma, with different objective testing sequences for adults, and children and young people aged 5 to 16.’
Effectively, this now means that for adults and over 16s, clinicians are advised to use a stepwise series of tests including eosinophil count, FeNO, spirometry and bronchial challenge in patients where the condition is suspected on clinical grounds.
To achieve QOF points in 2024/25, practices were expected to have a record of quality assured spirometry and one other objective test, such as FeNO or, bronchodilator reversibility or peak flow variability, between three months before or six months after diagnosis. They were also expected to do two objective tests in new patients joining the practice who have a diagnosis of asthma but no record of tests being done.
Swindon GP Dr Gavin Jamie and who runs the QOF database website said the change in diagnosis of asthma from doing several tests together to doing them in sequence ‘will be a change for practices and will require some new learning, but no more than other guideline changes’.
He added: ‘QOF has actually been simplified here. We don’t have the full rules yet but the guidance says that any of the tests will count for this indicator, and it is likely to be a single test rather than the two that were required in the past’.
This article first appeared on our sister site Management in Practice.
New Asthma Indicator AST012
The percentage of patients with a new diagnosis of asthma on or after 1 April 2025 with a record of an objective test between 3 months before or 3 months after diagnosis. Points: 15; Threshold: 45-80%.
Have your say
Please add your comment in the box below. You can include links, but HTML is not permitted. Please note that comments are not moderated before publication and the views expressed are those of the user and do not reflect the views of The Pharmacist. Remember that submission of comments is governed by our Terms and Conditions. You can also read our full guidelines on article comments here – but please be aware that you are legally liable for any libellous or offensive comments that you make. If you have a complaint about a comment or are concerned that a comment breaches our terms and conditions, please use the ‘Report this comment’ function to alert our web team.